Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Carcinoma, Transitional Cell 9Carcinoma, Renal Cell 8Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Neoplasm Metastasis 6Squamous Cell Carcinoma of Head and Neck 4Recurrence 3Glioblastoma 3Carcinoma, Neuroendocrine 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Sarcoma 2Neuroendocrine Tumors 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Diseases 1

Interventions

niraparib 1cabozantinib 1avelumab 1Sunitinib 1Paclitaxel 1Gemcitabine 1Everolimus 1Cisplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urothelial Cancer × avelumab × Clear all
NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
106 enrolled 36 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡